Law firm Kirby McInerney LLP is investigating Alvotech following the company's receipt of a complete response letter from the FDA on November 3, 2025, related to a failed facility inspection in July 2025. The news triggered a significant stock decline of 34.25%, dropping from $7.65 to $5.03 per share. The firm is determining whether securities law violations occurred and is seeking investors to participate in potential litigation.

Alvotech announced a share capital increase of USD 125,000 through the issuance of 12.5 million ordinary shares purchased by its subsidiary at USD 5.2 per share. The shares will be held as treasury shares to support the company's financial obligations including convertible bonds, warrants, and employee compensation. Total issued shares increased from 334 million to 346.5 million, while outstanding shares remained unchanged at 330.3 million.

Alvotech announced the issuance of 12.5 million new shares to its subsidiary at $5.2 per share, increasing treasury stock to support financial obligations including warrants and employee incentives. The company also reported positive top-line results from a pivotal pharmacokinetic study for AVT80, a proposed biosimilar to Entyvio®, meeting all primary endpoints.

Rosen Law Firm is investigating potential securities claims against Alvotech (NASDAQ: ALVO) following the company's November 2, 2025 announcement that the FDA issued a complete response letter for its AVT05 biologics license application, citing manufacturing deficiencies. The stock fell 34% on November 3, 2025, and investors are being encouraged to join a prospective class action lawsuit.

Rosen Law Firm is investigating potential securities claims against Alvotech (NASDAQ: ALVO) following allegations of materially misleading business information. The investigation was triggered after Alvotech received a complete response letter from the FDA on November 2, 2025, regarding deficiencies in its Biologics License Application for AVT05, causing the stock to fall 34% on November 3, 2025. The firm is preparing a class action lawsuit to recover investor losses.

Alvotech announced supply and commercialization agreements with Sandoz for multiple biosimilar candidates in Canada, Australia, and New Zealand. In Canada, the agreement covers one ophthalmology biosimilar as a prefilled syringe, while the Australia and New Zealand agreement encompasses three biosimilar candidates in immunology and gastroenterology. Sandoz will handle regulatory filings and commercialization while Alvotech retains development, clinical activities, and manufacturing responsibilities.

Alvotech announced supply and commercialization agreements with Sandoz for multiple biosimilar candidates in Canada, Australia, and New Zealand. In Canada, the agreement covers one ophthalmology biosimilar as a prefilled syringe, while in Australia and New Zealand, it encompasses three biosimilar candidates in immunology and gastroenterology. Sandoz will handle regulatory filings and commercialization while Alvotech retains development, clinical activities, and manufacturing responsibilities.

Rosen Law Firm is reminding investors in Gauzy Ltd., Coupang, Inc., and Alvotech of upcoming deadlines and ongoing investigations related to securities class action lawsuits. Gauzy investors have until February 6, 2026 to serve as lead plaintiff in a case alleging the company made false statements about its financial condition and failed to disclose insolvency risks at French subsidiaries.

The Rosen Law Firm is investigating potential securities claims against Alvotech (NASDAQ: ALVO) following the company's November 2, 2025 announcement that the FDA issued a complete response letter for its AVT05 biologics license application, citing manufacturing deficiencies. The stock fell 34% on November 3, 2025, prompting the law firm to prepare a class action lawsuit seeking recovery of investor losses.

The Rosen Law Firm is investigating potential securities claims against Alvotech (NASDAQ: ALVO) following the company's November 2, 2025 announcement that the FDA issued a complete response letter for its AVT05 biologics license application, citing manufacturing deficiencies. The stock fell 34% on November 3, 2025, prompting the law firm to prepare a class action lawsuit seeking recovery of investor losses.

Rosen Law Firm is soliciting investors who purchased securities of Gauzy Ltd. (NASDAQ: GAUZ) between March 11, 2025 and November 13, 2025 to join a class action lawsuit. The lawsuit alleges that Gauzy made false statements about its business while concealing that three French subsidiaries lacked financial means to meet debts, risking insolvency and default on senior secured debt facilities. The firm is also investigating potential securities claims for Coupang, Inc. (NYSE: CPNG) and Alvotech (NASDAQ: ALVO). The lead plaintiff deadline for Gauzy is February 6, 2026.

The Rosen Law Firm is investigating potential securities claims against Alvotech (NASDAQ: ALVO) following the company's November 2, 2025 announcement that the FDA issued a complete response letter for its AVT05 biologics license application, citing manufacturing deficiencies. The stock fell 34% on November 3, 2025, and investors are being encouraged to join a prospective class action lawsuit.